UK markets closed

Pulmonx Corporation (LUNG)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.77-0.49 (-7.75%)
At close: 04:00PM EDT
5.94 +0.17 (+2.95%)
After hours: 05:29PM EDT

Pulmonx Corporation

700 Chesapeake Drive
Redwood City, CA 94063
United States
650 364 0400

IndustryMedical Devices
Full-time employees279

Key executives

NameTitlePayExercisedYear born
Mr. David A. LehmanGeneral Counsel & Secretary651.39kN/A1961
Mr. Geoffrey Beran RoseChief Commercial Officer632.29kN/A1974
Mr. Steven S. WilliamsonCEO, President & DirectorN/AN/A1973
Mr. Mehul JoshiChief Financial OfficerN/AN/A1961
Mr. Sri RadhakrishnanChief Technical OfficerN/AN/AN/A
Ms. Marcee M. MaroneyVice President of MarketingN/AN/A1970
Sarah HuberVice President of Sales (U.S.)N/AN/AN/A
Ms. Lisa PaulChief People OfficerN/AN/A1964
Mr. Jérôme ErathSenior VP & GM of Europe Middle-East & AfricaN/AN/AN/A
Mr. John B. McKuneVP & Corporate ControllerN/AN/A1976
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Corporate governance

Pulmonx Corporation’s ISS governance QualityScore as of 1 June 2024 is 10. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.